Rare Skin Allergy Warning Spreads To Nexium 24HR

FDA approves request after Nexium 24HR marketer Haleon responded March to changes-being-effected letter asking for label change to the delayed-release PPI.

• Source: Shutterstock

Nexium 24HR is the second OTC proton pump inhibitor available in the US to add a label warning about a potential risk of rare skin reaction, a change firms marketing generic equivalents also are expected to make.

The FDA Center for Drug Evaluation and Research approved a request earlier in September from Nexium 24HR marketer

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Ingredients & Safety

More from HBW Insight